Human COMP Protein (His Tag)

EDM1,EPD1,MED,PSACH,THBS5

• 100ug (NPP2044) Please inquiry

Catalog Number	P10173-H08H
Organism Species	Human
Host	Human Cells
Synonyms	EDM1,EPD1,MED,PSACH,THBS5
Molecular Weight	The mature form of human COMP consists of 748 amino acids after removal of the signal peptide and predicts a molecular mass of 82.4 kDa. As a result of glycosylation, the apparent molecular mass of rhCOMP is approximately 120-130 kDa in SDS-PAGE under reducing conditions.
predicted N	Gln 21
SDS-PAGE
Purity	> 95 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the human COMP (NP_000086.2) precusor (Met 1-Ala 757) was expressed with a C-terminal polyhistidine tag.
Bio-activity
Research Area	Signaling |Signal Transduction |Cytoskeleton / ECM |Extracellular Matrix |ECM Proteins |Thrombospondin |
Formulation	Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	Cartilage Oligomeric Matrix Protein (COMP), also referred to as Thrombospondin-5, is a non-collagenous extracellular matrix (ECM) protein and belongs to the subgroup B of the thrombospondin protein family. This protein is expressed primarily in cartilage, ligament, and tendon, and binds to other ECM proteins such as collagen I, II and IX with high affinities depending on the divalent cations Zn2+ or Ni2+. COMP is a secreted glycoprotein that is important for growth plate organization and function. It is suggested to play a role in cell growth and development, and recent studies have revealed the possible mechanism that it protects cells against death by elevating members of the IAP (inhibitor of apoptosis protein) family of survival proteins. Mutations in COMP cause two skeletal dysplasias, pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (EDM1), and up-regulated expression of COMP are observed in rheumatoid arthritis and certain carcinomas.
Reference	Posey KL, et al. (2004) Role of TSP-5/COMP in pseudoachondroplasia. Int J Biochem Cell Biol. 36(6): 1005-12. Chen FH, et al. (2005) Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. J Biol Chem. 282(34): 24591-8. Posey KL, et al. (2008) The role of cartilage oligomeric matrix protein (COMP) in skeletal disease. Curr Drug Targets. 9(10): 869-77. Tan K, et al. (2009) The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding. FASEB J. 23(8): 2490-501.